Cryptococcal lipid metabolism: phospholipase B1 is implicated in transcellular metabolism of macrophage-derived lipids.
Cryptococci survive and replicate within macrophages and can use exogenous arachidonic acid for the production of eicosanoids. Phospholipase B1 (PLB1) has a putative, but uninvestigated, role in these processes. We have shown that uptake and esterification of radiolabeled arachidonic, palmitic, and oleic acids by the Cryptococcus neoformans var. grubii H99 wild-type strain and its PLB1 deletion mutant strain (the Deltaplb1 strain) are independent of PLB1, except under hyperosmolar stress. Similarly, PLB1 was required for metabolism of 1-palmitoyl lysophosphatidylcholine (LysoPC), which is toxic to eukaryotic cell membranes, under hyperosmolar conditions. During both logarithmic and stationary phases of growth, the physiologically relevant phospholipids, dipalmitoyl phosphatidylcholine (DPPC) and dioleoyl phosphatidylcholine, were taken up and metabolized via PLB1. Exogenous DPPC did not enhance growth in the presence of glucose as a carbon source but could support it for at least 24 h in glucose-free medium. Detoxification of LysoPC by reacylation occurred in both the H99 wild-type and the Deltaplb1 strains in the presence of glucose, but PLB1 was required when LysoPC was the sole carbon source. This indicates that both energy-independent (via PLB1) and energy-dependent transacylation pathways are active in cryptococci. Phospholipase A(1) activity was identified by PLB1-independent degradation of 1-palmitoyl-2-arachidonoyl phosphatidylcholine, but the arachidonoyl LysoPC formed was not detoxified by reacylation. Using the human macrophage-like cell line THP-1, we demonstrated the PLB1-dependent incorporation of macrophage-derived arachidonic acid into cryptococcal lipids during cryptococcus-phagocyte interaction. This pool of arachidonate can be sequestered for eicosanoid production by the fungus and/or suppression of host phagocytic activity, thus diminishing the immune response.
Wright
Lesley C
LC
Centre for Infectious Diseases and Microbiology, Level 3, ICPMR Building, Westmead Hospital, Westmead NSW 2145, Australia. lesleyw@icpmr.wsahs.nsw.gov.au
Santangelo
Rosemary M
RM
Ganendren
Ranjini
R
Payne
Jackie
J
Djordjevic
Julianne T
JT
Sorrell
Tania C
TC
D016718:Arachidonic Acid / Q000493:pharmacokinetics; D002460:Cell Line; D003453:Cryptococcosis / Q000201:enzymology / Q000209:etiology; D003454:Cryptococcus / Q000201:enzymology / Q000254:growth & development / Q000378:metabolism*; D006801:Humans; D050356:Lipid Metabolism; D008245:Lysophospholipase / Q000378:metabolism / Q000502:physiology*; D008264:Macrophages / Q000201:enzymology / Q000378:metabolism* / Q000382:microbiology; D019301:Oleic Acid / Q000493:pharmacokinetics; D009995:Osmosis; D019308:Palmitic Acid / Q000493:pharmacokinetics; D010587:Phagocytosis; D010743:Phospholipids / Q000493:pharmacokinetics; D053586:Virus Internalization
D010743:Phospholipids; D016718:Arachidonic Acid; D019301:Oleic Acid; D019308:Palmitic Acid; D008245:Lysophospholipase